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all 12 features were associated with IDS satisfaction (P < 0.01),
but only discrepancy scores for “easy to control blood sugar,”
“reduces my reluctance to use insulin,” “easy to get insulin dose
needed,” and “convenient to use” were signiﬁcant predictors of
IDS satisfaction, as were HbA1C and health status (R2 = 0.31;
P < 0.05).CONCLUSION: IDS features are important to patients
with T2DM; therefore resolving discrepancies between feature
importance and patient evaluation of IDS features may improve
patient satisfaction and facilitate diabetes management.
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OBJECTIVE: Understanding what Insulin Delivery System (IDS)
features are important to patients with type 2 diabetes (T2DM) is
essential to the development of improved IDSs. The objective of
this study was to determine what characteristics are associated
with (or predict) users of insulin pens vs. vial and syringe
(V/S). METHODS: Patients with T2DM were administered a
web-based survey that included questions about demographics,
comorbidities, glycemic control, and insulin use; ratings of the
importance of 12 IDS features; and an evaluation of features of the
current IDS. Two logistic regression analyses were performedwith
the respondent characterization of their IDS as insulin pen or V/S
as dependent variables. Variables signiﬁcantly (p < 0.05) associ-
ated with dependent variables, a priori, were included as indepen-
dent variables. RESULTS: A total of 681 insulin-using
T2 patients in the US (52% female; mean age = 57 years; 88%
Caucasian; 85% on insulin >1 year, 86% used V/S) participated in
the survey. Signiﬁcant predictors (p < 0.05) for insulin pen use:
Patient: “is a homemaker” (OR, 0.177), “agrees their IDS does
not interfere with plans for short trips” (OR, 5.942), “agrees their
IDS is easy to carry away from home” (OR, 0.054), “rates their
IDS ease to carry away from home as ‘important’” (OR, 2.558),
“uses Byetta” (OR, 0.067), “injects insulin >twice/day” (OR,
0.235), “has never been diagnosed with depression” (OR, 0.367).
Signiﬁcant predictors (p < 0.05) of V/S use: Patient: “is dissatisﬁed
with their IDS regarding insulin use” (OR, 111.767), “disagrees
their IDS makes it easy getting ready for next dose” (OR, 0.006),
“has cancer” (OR, <0.0001), “uses Glargine” (OR, <0.0001), “is
not using insulin lispro” (OR, 0.013), “has a higher number of
adults in the household”, “rates IDS discreetness as ‘least impor-
tant’ ” (OR, 206.347). CONCLUSION: Overall, multiple injec-
tions and need for portability predict insulin pen use; not valuing
discreteness and dissatisfaction predict V/S use.
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OBJECTIVE: To examine the effects of sociodemographic
characteristics, health status, comorbidity, provider, medication
and ﬁnancial variables on insulin initiation behavior for type 2
diabetics on multiple oral antidiabetic medications. METHODS:
The 2002–2006 MarketScan Research Databases were used to
study the health care utilization and expenditure patterns of
adults with type 2 diabetes in employer-sponsored health plans in
the United States. The utilization patterns of 38,768 patients
with Type 2 diabetes who were adherent to one oral antidiabetic
medication and added a second oral medication for at least 6
months were analyzed. Two outcomes were examined: insulin
initiation within 12 months and the amount of time to insulin
initiation. Multivariate logistic models were used to estimate the
effects of the explanatory variables on the likelihood of insulin
initiation. Cox proportional hazard models with prescription
drug and ofﬁce visit copayments as time-varying covariates were
used to estimate the effects of the explanatory variables on the
amount of time to insulin initiation. RESULTS: A total of 16.5%
of patients initiated insulin within one year. A variety of deter-
minants were associated with insulin initiation within a year: age
(Adjusted Odds Ratio 0.982, 95% CI (0.980, 0.985) ), health
status indicated by the presence of factors such as heart disease
(AOR 1.48 (1.317, 1.654)), myocardial infarction (AOR 1.32,
(1.068, 1.640)), diabetic retinopathy (AOR 1.26, (1.120,
1.406)), the number of nondiabetes medications (AOR 1.03,
(1.030, 1.039)), and insulin copayments (AOR 0.998, (0.995,
1.000)). The amount of time to insulin initiation was also
affected by similar factors. CONCLUSION: Health status
appears to be the strongest predictor of insulin initiation in
patients initiating insulin for type 2 diabetics who are adherent to
oral medications. Providers, health plans and employers should
be aware of the factors that inﬂuence the addition of a medica-
tion to a treatment regimen for chronically-ill patients.
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OBJECTIVE: To evaluate the one to two year changes in health
care costs and disease-related process measures associated with
the a disease management program initiated in 2002 for
higher-risk, higher-expenditure adult fee-for-service Medicaid
clients with diabetes in the State of Colorado, United States.
METHODS: This retrospective database analysis employed a
pre-post and propensity-score matched analysis assessing direct
costs from the perspective of a public payer. Data analyzed
included comprehensive medical and pharmacy claims, patient
demographics (i.e., age, gender, race), medical and pharmacy
resource utilization claims (e.g., selected prescription drug use
and laboratory testing procedures conducted), diagnostic
information, and eligibility/enrollment status. Multivariate re-
gression techniques were utilized to ascertain differences between
the disease management and matched comparator groups.
RESULTS: Of the 388 Medicaid clients that were eligible and
initially contacted for enrollment, 41 (11%) completed at least
one year and 10 (3%) completed an entire two years of the
program. Enrollees were typically older, female, and of a non-
white race or ethnicity. Among those enrolled for one year or
more, signiﬁcant decreases in overall medical costs were observed
relative to matched comparators during both Year 1 and Year 2
of the interventions (Year 1 = 44.4% decrease, p < 0.001 and
Year 2 = 67.1% decrease, p < 0.010). Overall pharmacy costs
were lower for the disease management group during Year 2
(64.0% decrease, p = 0.013), as were diabetes-related pharmacy
costs (64.9%, p = 0.005). Effect sizes based upon multivariate
analyses were observed to be small. CONCLUSION: Based on
this analysis of 41 clients completing at least one year of diabetes
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disease management program, signiﬁcantly lower costs were
noted during Year 1 which continued and expanded through
Year 2 relative to matched comparators. Beyond claims analyses,
however, incremental cost-effectiveness of disease management
programs must also consider program-speciﬁc expenditures and
clinical outcome measures.
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OBJECTIVE: To examine whether physicians’ practice specialties
are associated with the types of anti-diabetic treatments for
patients with type 2 diabetes (T2D). METHODS: A retrospective
study design was used based. All T2D patients’ (N = 1,819,323)
medication histories in a 12 month period were examined and
classiﬁed into 9 treatment types (no anti-diabetic medication, oral
anti-diabetic medication (OAD), basal insulin only, prandial
insulin only, basal insulin with OAD, prandial insulin with OAD,
basal/prandial insulin, basal/prandial insulin(including premixed
insulins) with OAD, other insulin regimens). Physicians practice
specialties were classiﬁed into ﬁve categories (family medicine,
internal medicine, other primary care specialists, endocrino-
logists, other specialties). A two-way contingency table was
created with Chi-square test and Fisher’s exact test to examine the
possible association between physicians’ practice specialty and the
types of anti-diabetic treatments they prescribed.RESULTS: Both
the Chi-square test and the Fisher’s exact test had p < 0.0001,
indicating that physicians’ practice specialty and their patients’
anti-diabetic treatment choices were statistically signiﬁcantly
associated. The contingency table suggests that the percent of
patients receiving no anti-diabetic medications varied across spe-
cialties from 36.0% in patients who visited an endocrinologist to
49% and 52% in patients who visited a family medicine physician
or internist, respectively. The percent of patients receiving OAD
only varied across specialties from 33.1% in patients who visited
an endocrinologist to 46.8% in patients who saw a family medi-
cine physician, and 43.6% in patients under the care of an
internist. And the percent of patients receiving insulin as part of
their regimen varied across specialties from4.12% in patientswho
visited a family medicine physician to 12.3% in patients who
visited an endocrinologist. CONCLUSION: Physicians’ practice
specialty is strongly associated with anti-diabetic medications
prescribed for patients with T2D. Further research to examine
outcomes differences across physician specialties is needed.
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OBJECTIVE: In the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial (a 10-year, 70 site study of diabetes
treatments), four health state preference measures (HSPMs),
which vary in theoretical constructs, are being collected. Our
objectives were to compare baseline values of the feeling
thermometer (FT), the Health Utilities Index, Mark 2 and Mark
3 (HUI-2 and HUI-3), and the SF-6D, derived from the Short
Form 36 and to explore associations between each HSPM
and 29 baseline clinical and demographic characteristics.
METHODS: Participants (n = 2053) were randomly selected for
the cost effectiveness sub-study of ACCORD. To compare the
HSPMs, we determined correlations between the measures, by
overall score and within each quartile range. We used multivari-
ate regression models to identify relationships between clinical
and demographic characteristics for each HSPM. RESULTS:
The mean  standard deviation HSPMs were: FT = 0.756 
0.167, HUI-2 = 0.823  0.146, HUI-3 = 0.712  0.260, and
SF-6D = 0.684  0.085. Although all 4 measures were signiﬁ-
cantly correlated with each other (Spearman r = 0.29–0.84
(p < 0.0001); relationships were weaker between the FT and the
other measures (0.29–0.38) and strongest between the two HUI
measures (0.84). By quartiles of HSPM, signiﬁcant correlations
were more common at the lowest quartile. In multivariate
regression analyses, we identiﬁed signiﬁcant associations
(p < 0.01) between HSPM values and age (positive), gender
(lower for females), years of education (positive), and race
(lower for non-white). Clinical characteristics inversely associ-
ated with HSPMs were duration of diabetes, current smoking,
secondary cardiovascular disease, total cholesterol, waist cir-
cumference, and body mass index. Number of medications
(blood pressure, glycemic, or lipid) were not signiﬁcantly
associated with HSPMs. Glycosylated hemoglobin values were
inversely related to FT only. CONCLUSION: Our results
suggest that the four instruments,result in different HSPM
values. Relationships with clinical and demographic variables
vary by HSPM. Therefore, results of cost-effectiveness results
may be impacted by the speciﬁc HSPM applied.
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OBJECTIVE: The aim of this study was to collect comparable
and reliable data about consumption of drugs for treatment of
diabetes mellitus in Slovakia during the period 1996–2006.
METHODS: Data of wholesalers (following ATC/DDD), who
are legally obliged provide this information to the Slovak Insti-
tute for Drug Control, was used for the analysis. The results
were expressed in the numbers of the packages, ﬁnance units (€)
and deﬁned daily doses per 1000 inhabitants per day (DID).
RESULTS: The collected data shows a moderate increases in the
antidiabetic’s consumption from 1996 to 2006 in term of DID (in
1996 (27.03), in 2001 (32.62) and in 2006 (37.90). A slight
increase in A10AB group (Insulins and analogues, fast-acting) in
1996 (1.88), in 2001 (2.79) and in 2006 (4.64), a slight decrease
in A10AC group (Insulins and analogues, intermediate-acting) in
1996 (4.25), in 2001 (3.74) and in 2006 (3.35), a moderate
increase in A10AD (Insulins and analogues, intermediate-acting
combin.) in 1996 (0.51), in 2001 (2.36) and in 2006 (3.25), a
steady increase in A10AE (Insulins and analogues, long-acting) in
2001 (0.03) and in 2006 (0.89), a dramatic increase in A10BA
(Biguanides) in 1996 (4.45), in 2001 (5.75) and in 2006 (9.46),
relatively stable consumption in A10BB (Sulfonamides, urea
derivatives) in 1996 (15.33), in 2001 (17.19) and in 2006 (14.76)
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